Lifetime Citizen Portal Access — AI Briefings, Alerts & Unlimited Follows
Committee hears testimony and advances multistate ibogaine research bill after veteran testimony
Loading...
Summary
HB 2075 (HOPE Treatment Act) — a bill to join a multistate consortium to accelerate research on ibogaine and derivatives — drew personal testimony from veterans and researchers and advanced from committee by recorded vote (18-3). Supporters argued for faster trials and access; members probed cost, commercialization and safeguards.
The House Health Committee took testimony on HB 2075, the HOPE Treatment Act, and voted to advance the bill after extensive questioning from members about safety, costs and commercialization. The panel heard personal testimony from veterans and research experts before voting 18-3 to send the bill onward.
Sponsor framed the bill around Tennessee's high rates of opioid use disorder and veteran overdose deaths and said expedited multistate trials could secure FDA breakthrough therapy designation for ibogaine derivatives. "Ibogaine treatment offers a potential solution," the sponsor said, stressing the state's role in contributing critical data for FDA trials.
Sean Ryan (Speaker 22), who introduced himself to the committee and described a long history of substance use and post-traumatic symptoms, testified about receiving ibogaine treatment in Mexico three years earlier. Ryan described a medically supervised, 12-hour dosing period monitored by EKG and an unpleasant acute reaction. "I have not had any booze...or cocaine...in over 3 years," he told the committee, attributing sustained recovery and improved PTSD and TBI symptoms to the single treatment and to follow-up therapy.
Jeffrey Lawrence (Speaker 24), research director at the Reason Foundation, explained the multistate consortium model the bill would join. He said Texas initiated the approach with a $50 million appropriation and that the consortium pairs state appropriations with private matching funds; the private developer would hold IND responsibility and technical ownership of resulting intellectual property while member states could take part in profit-sharing arrangements. Lawrence said the research would likely target a synthetic derivative (e.g., noribogaine) and that the IND had not yet been submitted.
Members focused questions on safety protocols, trial design, participant eligibility, cost and access for veterans. Committee members asked whether treatment would be affordable — witnesses said initial out-of-pocket costs for foreign treatment runs were in the thousands (one witness cited approximately $8,000 for his treatment in Mexico) and suggested state investment and multistate partnerships could reduce costs and host trials locally. Members also asked about intellectual property and commercialization; witnesses said synthetic derivatives have been pursued by private companies, and that patentability and profit-sharing were part of the consortium design.
The committee called the previous question and voted to advance HB 2075 as amended (18 ayes, 3 nays). Supporters said the bill creates a pathway for Tennessee to host FDA-regulated trials and help veterans and people with opioid use disorder access new treatments; skeptics urged caution on public investment and private commercialization structures.
What’s next: HB 2075 moves to the Finance/Ways and Means process for consideration of funding and then to later committees. The record shows vocal personal testimony and technical policy discussion about safety, commercialization, and the role of state funding in private-public research partnerships.
